BMY - Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
2024-06-03 04:06:40 ET
Summary
- S&P 500 operating EPS growth was solid at 6.4% in Q1, but critics argue that excluding profits from top tech stocks shows less impressive growth.
- Bristol-Myers Squibb faces a soft growth outlook, but high expected free cash flow and steady sales suggest today's valuation is simply too low.
- With a dividend yield now near 6%, I outline key price levels to monitor in this beaten-down pharma stock.
The first-quarter earnings season is largely in the books. S&P 500 operating EPS growth was solid at 6.4%. Critics contend that if you back out the very impressive profits from the Magnificent 7 stocks, then the market’s earnings growth rate is less sublime. ...
Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss